Common Contracts
104 similar Employment Agreement contracts by Dynatrace, Inc., Korro Bio, Inc., MeridianLink, Inc., others
AVROBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • February 14th, 2024 • AVROBIO, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 26th day of January 2022 (the “Effective Date”), between AVROBIO, Inc., a Delaware corporation (the “Company”), and Azadeh Golipour (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 30th, 2024 • Triller Corp. • Services-computer programming, data processing, etc. • California
This Amended and Restated Employment Agreement (“Agreement”) is made between Triller Platform Inc., a Delaware corporation with its headquarters located at 2121 Avenue of the Stars, Suite 2350, Los Angeles, California, 90067 (the “Company”), and Prem Parameswaran, residing at 3 Sycamore Court, Purchase, NY 10577 (the “Executive”). The Agreement is effective as of December 7, 2023 (the “Effective Date”) and with certain parts being effective as of the closing of the Company’s first public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated on or around April 2022 (the “P
EMPLOYMENT AGREEMENTEmployment Agreement • January 30th, 2024 • Triller Corp. • Services-computer programming, data processing, etc. • California
This Employment Agreement (“Agreement”) is made between Triller Corp., a Delaware corporation (the “Company”), and _____________________ (the “Executive”) and is effective as of the closing of the Company’s first public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the [Employment Agreement] between the Executive and the Company dated ______ (the “Prior Agreement”), and (ii) any offer letter, employment agreement or severance agreement.
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • December 22nd, 2023 • Karuna Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Second Amended and Restated Employment Agreement (“Agreement”) is made between Karuna Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Miller, Ph.D. (the “Executive”) and is made effective as of December 22, 2023 (the “Effective Date”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • December 22nd, 2023 • Karuna Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Second Amended and Restated Employment Agreement (“Agreement”) is made between Karuna Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason Brown (the “Executive”) and is made effective as of December 22, 2023 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • December 22nd, 2023 • Karuna Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made between Karuna Therapeutics, Inc., a Delaware corporation (the “Company”), and William Meury (the “Executive”) and is made effective as of December 22, 2023 (the “Effective Date”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • December 22nd, 2023 • Karuna Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Second Amended and Restated Employment Agreement (“Agreement”) is made between Karuna Therapeutics, Inc., a Delaware corporation (the “Company”), and Stephen Brannan, M.D. (the “Executive”) and is made effective as of December 22, 2023 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 1st, 2023 • Korro Bio, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Shelby Walker (the “Executive”) and is effective as of the date it is fully executed (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated March 29, 2023 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • December 1st, 2023 • Korro Bio, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Steven Colletti, Ph.D. (the “Executive”) and is effective as of the date it is fully executed (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated January 20, 2023 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • December 1st, 2023 • Korro Bio, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Todd Chappell (the “Executive”) and is effective as of the date it is fully executed (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated March 3, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • November 14th, 2023 • Korro Bio, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Vineet Agarwal (the “Executive”) and is effective as of the date it is fully executed (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated March 12, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • November 14th, 2023 • Korro Bio, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Ram Aiyar, Ph.D. (the “Executive”) and is effective as of the date it is fully executed (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated October 13, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2023 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and Ram Chuttani, M.D. (the “Executive”) and is made effective as of the closing of the transactions contemplated by that certain Business Combination Agreement, dated as of February 9, 2023, by and between the Company, Compute Health Acquisition Corp (“CPUH”), Allurion Technologies Holdings, Inc. (“New Allurion”) and certain other specified parties thereto (the “Business Combination Agreement”). Except with respect to the Restrictive Covenants and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company and any of its subsidiaries regarding the subject matter herein, including, without limitation, the Employment Agreement, effective November 1, 2017, by and between the Company and the Executive (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2023 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and Chris Geberth (the “Executive”) and is made effective as of the closing of the transactions contemplated by that certain Business Combination Agreement, dated as of February 9, 2023, by and between the Company, Compute Health Acquisition Corp (“CPUH”), Allurion Technologies Holdings, Inc. (“New Allurion”) and certain other specified parties thereto (the “Business Combination Agreement”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company and any of its subsidiaries regarding the subject matter herein, including, without limitation, the Offer Letter, dated October 23, 2020, by and between the Company and the Executive (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2023 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and Shantanu Gaur, M.D. (the “Executive”) and is made effective as of the closing of the transactions contemplated by that certain Business Combination Agreement, dated as of February 9, 2023, by and between the Company, Compute Health Acquisition Corp (“CPUH”), Allurion Technologies Holdings, Inc. (“New Allurion”) and certain other specified parties thereto (the “Business Combination Agreement”). Except with respect to the Restrictive Covenants and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company and any of its subsidiaries regarding the subject matter herein, including, without limitation, the Employment Agreement, effective January 1, 2017, by and between the Company and the Executive (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 2nd, 2023 • Dynatrace, Inc. • Services-prepackaged software • Massachusetts
This Employment Agreement (this “Agreement”) is made as of June 1, 2023 between Dynatrace LLC, a Delaware limited liability company, Dynatrace, Inc., a Delaware corporation that is the parent of Dynatrace LLC (“Parent”), and Daniel Zugelder (the “Executive”), and is effective as of the date the Executive commences employment with Dynatrace LLC, which shall be no later than July 5, 2023 (the “Effective Date”). Dynatrace LLC, Parent and their respective subsidiaries and other controlled affiliates are collectively referred to herein as the “Company,” and the duties of the Company set forth in this Agreement may be discharged by any entity within that definition.
EMPLOYMENT AGREEMENTEmployment Agreement • June 27th, 2023 • Allurion Technologies Holdings, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and Chris Geberth (the “Executive”) and is made effective as of the closing of the transactions contemplated by that certain Business Combination Agreement, dated as of February 9, 2023, by and between the Company, Compute Health Acquisition Corp (“CPUH”), Allurion Technologies Holdings, Inc. (“New Allurion”) and certain other specified parties thereto (the “Business Combination Agreement”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company and any of its subsidiaries regarding the subject matter herein, including, without limitation, the Offer Letter, dated October 23, 2020, by and between the Company and the Executive (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 27th, 2023 • Allurion Technologies Holdings, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and Shantanu Gaur, M.D. (the “Executive”) and is made effective as of the closing of the transactions contemplated by that certain Business Combination Agreement, dated as of February 9, 2023, by and between the Company, Compute Health Acquisition Corp (“CPUH”), Allurion Technologies Holdings, Inc. (“New Allurion”) and certain other specified parties thereto (the “Business Combination Agreement”). Except with respect to the Restrictive Covenants and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company and any of its subsidiaries regarding the subject matter herein, including, without limitation, the Employment Agreement, effective January 1, 2017, by and between the Company and the Executive (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 27th, 2023 • Allurion Technologies Holdings, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (“Agreement”) is made between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and Ram Chuttani, M.D. (the “Executive”) and is made effective as of the closing of the transactions contemplated by that certain Business Combination Agreement, dated as of February 9, 2023, by and between the Company, Compute Health Acquisition Corp (“CPUH”), Allurion Technologies Holdings, Inc. (“New Allurion”) and certain other specified parties thereto (the “Business Combination Agreement”). Except with respect to the Restrictive Covenants and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company and any of its subsidiaries regarding the subject matter herein, including, without limitation, the Employment Agreement, effective November 1, 2017, by and between the Company and the Executive (the “Prior Agreement”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 25th, 2023 • Dynatrace, Inc. • Services-prepackaged software • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made between Dynatrace LLC, a Delaware limited liability company, Dynatrace, Inc., the parent of Dynatrace LLC (“Parent”) and Rick McConnell (the “Executive”) and is effective as of March 23, 2023 (the “Effective Date”). Dynatrace LLC, Parent and their respective subsidiaries and other controlled affiliates are collectively referred to herein as the “Company,” and the duties of the Company set forth in this Agreement may be discharged by any entity within that definition.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 25th, 2023 • Dynatrace, Inc. • Services-prepackaged software • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made between Dynatrace LLC, a Delaware limited liability company, Dynatrace, Inc., the parent of Dynatrace LLC (“Parent”) and Stephen Pace (the “Executive”) and is effective as of March 23, 2023 (the “Effective Date”). Dynatrace LLC, Parent and their respective subsidiaries and other controlled affiliates are collectively referred to herein as the “Company,” and the duties of the Company set forth in this Agreement may be discharged by any entity within that definition.
EMPLOYMENT AGREEMENTEmployment Agreement • March 9th, 2023 • MeridianLink, Inc. • Services-prepackaged software • California
This Employment Agreement (“Agreement”) is made between MeridianLink, Inc., a Delaware corporation (including its successors and assigns, the “Company”), and Sean Blitchok (the “Executive”) and is effective as of May 25, 2022 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 9th, 2023 • MeridianLink, Inc. • Services-prepackaged software • California
This Amended and Restated Employment Agreement (“Agreement”) is made between MeridianLink, Inc., a Delaware corporation (including its successors and assigns, the “Company”), and Christopher Maloof (the “Executive”) and is effective as of June 15, 2022 (the “Effective Date”). Except with respect to the Restrictive Covenants Obligations, the Continuing Obligations, and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive, Project Angel Parent LLC and the Company (the “Prior Agreement”) and (ii) any offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 9th, 2023 • MeridianLink, Inc. • Services-prepackaged software • California
This Employment Agreement (“Agreement”) is made among Project Angel Parent LLC, a Delaware limited liability company (including its successors and assigns, the “Parent”), MeridianLink, Inc., a California corporation and wholly-owned subsidiary of Parent (including its successors and assigns, the “Company”), and Nicolaas Vlok (the “Executive”) and is effective as of the effectiveness of the Parent’s Form S-1 Registration Statement with the U.S. Securities and Exchange Commission (the “Effective Date”). Except with respect to the Restrictive Covenants Obligations (as modified herein), the Continuing Obligations, and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Parent, the Company, or MeridianLink, Inc., a Delaware corporation regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and MeridianLink, Inc., a Delaware corporation dated Se
EMPLOYMENT AGREEMENTEmployment Agreement • November 21st, 2022 • Dynatrace, Inc. • Services-prepackaged software • Massachusetts
This Employment Agreement (“Agreement”) is made as of November 15, 2022 (the “Effective Date”) between Dynatrace LLC, a Delaware limited liability company, Dynatrace, Inc., the parent of the Company (“Parent”) and Jim Benson (the “Executive”). Dynatrace LLC, Parent and their respective subsidiaries and other controlled affiliates are collectively referred to herein as the “Company,” and the duties of the Company set forth in this Agreement may be discharged by any entity within that definition.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 16th, 2022 • MeridianLink, Inc. • Services-prepackaged software • California
This Amended and Restated Employment Agreement (“Agreement”) is made between MeridianLink, Inc., a Delaware corporation (including its successors and assigns, the “Company”), and Christopher Maloof (the “Executive”) and is effective as of June 15, 2022 (the “Effective Date”). Except with respect to the Restrictive Covenants Obligations, the Continuing Obligations, and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive, Project Angel Parent LLC and the Company (the “Prior Agreement”) and (ii) any offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • May 26th, 2022 • Dynatrace, Inc. • Services-prepackaged software • Massachusetts
This Employment Agreement (“Agreement”) is made between Dynatrace LLC, a Delaware corporation (the “Company”), and Kevin C. Burns (the “Executive”) and is effective as of the effectiveness of the Company’s Form S-1 Registration Statement with the U.S. Securities and Exchange Commission (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement, the Continuing Obligations, and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement (the “Prior Agreements”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 26th, 2022 • Dynatrace, Inc. • Services-prepackaged software • Massachusetts
This Employment Agreement (“Agreement”) is made between Dynatrace LLC, a Delaware corporation (the “Company”), and Steven Pace (the “Executive”) and is effective as of the effectiveness of the Company’s Form S-1 Registration Statement with the U.S. Securities and Exchange Commission (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement, the Continuing Obligations, and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement (the “Prior Agreements”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 25th, 2022 • MeridianLink, Inc. • Services-prepackaged software • California
This Employment Agreement (“Agreement”) is made between MeridianLink, Inc., a Delaware corporation (including its successors and assigns, the “Company”), and Sean Blitchok (the “Executive”) and is effective as of May 25, 2022 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 2nd, 2022 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made by and between Magenta Therapeutics, Inc., a Delaware corporation (the “Company”), and David Nichols (the “Executive”) and is effective as of May 2, 2022 (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 2nd, 2022 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made by and between Magenta Therapeutics, Inc., a Delaware corporation (the “Company”), and Thomas Beetham (the “Executive”) and is effective as of May 2, 2022 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 3rd, 2022 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Cullinan Oncology, Inc., a Delaware corporation (the “Company”), and Jeffrey Jones (the “Executive”) and is effective as of the Executive’s first day of employment with the Company, which will be February 28, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any term sheet.
EMPLOYMENT AGREEMENTEmployment Agreement • January 3rd, 2022 • Amylyx Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and James Frates (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated January 25, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • January 3rd, 2022 • Amylyx Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Margaret Olinger, M.B.A. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated May 13, 2019 and later amended August 1, 2019 and twice amended February 19, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • January 3rd, 2022 • Amylyx Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Patrick D. Yeramian, M.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 12, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment agreement between the Executive and the Company dated March 18, 2019 and later modified November 26, 2019 and later twice amended February 19, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
